Monitoring EGFR mutation status with cell-free DNA: a prospective exploratory analyses of phase Ib study of osimertinib plus ramucirumab in lung adenocarcinoma patients with EGFR T790M mutation

Monitoring EGFR mutation status with cell-free DNA: a prospective exploratory analyses of phase Ib study of osimertinib plus ramucirumab in lung adenocarcinoma patients with EGFR T790M mutation - Exploratory analyses of Phase Ib study of osimertinib with ramucirumab

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030164

Enrollment

Registered

2017-11-29

Start date

2017-11-29

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

Osimertinib + ramucirumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Those who participate in the phase Ib trial of osimertinib+ramucirumab, and can provide blood sample (mandatory) and tissue sample (optional). 2) Written informed consent was obtained.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Change of EGFR T790M mutation during treatment	—

Countries

Japan

Contacts

Public ContactHiroaki Akamatsu

Wakayama Medical University Third Department of Internal Medicine

h-akamat@wakayama-med.ac.jp073-441-0619

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026